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Huntington’s disease (HD), caused by a CAG repeat expansion in the huntingtin (HTT) gene, is characterized
by abnormal protein aggregates and motor and cognitive dysfunction. Htt protein is ubiquitously expressed,
but the striatal medium spiny neuron (MSN) is most susceptible to dysfunction and death. Abnormal gene
expression represents a core pathogenic feature of HD, but the relative roles of cell-autonomous and non-
cell-autonomous effects on transcription remain unclear. To determine the extent of cell-autonomous dysre-
gulation in the striatum in vivo, we examined genome-wide RNA expression in symptomatic D9-N171-98Q
(a.k.a. DE5) transgenic mice in which the forebrain expression of the first 171 amino acids of human Htt
with a 98Q repeat expansion is limited to MSNs. Microarray data generated from these mice were compared
with those generated on the identical array platform from a pan-neuronal HD mouse model, R6/2, carrying two
different CAG repeat lengths, and a relatively high degree of overlap of changes in gene expression was
revealed. We further focused on known canonical pathways associated with excitotoxicity, oxidative
stress, mitochondrial dysfunction, dopamine signaling and trophic support. While genes related to excito-
toxicity, dopamine signaling and trophic support were altered in both DE5 and R6/2 mice, which may be
either cell autonomous or non-cell autonomous, genes related to mitochondrial dysfunction, oxidative
stress and the peroxisome proliferator-activated receptor are primarily affected in DE5 transgenic mice, indi-
cating cell-autonomous mechanisms. Overall, HD-induced dysregulation of the striatal transcriptome can be
largely attributed to intrinsic effects of mutant Htt, in the absence of expression in cortical neurons.
INTRODUCTION
The widespread expression of the huntingtin (Htt) protein in
Huntington’s disease (HD) immediately raises the question
of the etiology of the selective vulnerability that is observed
in distinct populations of neurons in this disease. Although
there is increased recognition of vulnerability of neurons
outside the striatum, the medium size spiny neuron (MSN)
remains the most affected neuronal subtype. The regional
distribution of the described huntingtin-interacting proteins
does not adequately explain this specificity (1–3), and there-
fore the question of ‘murder versus suicide’ persists. Does
the mutation in huntingtin act cell autonomously, leading to
dysfunction and degeneration of MSNs, i.e. ‘suicide’? Or,
does the mutation act non-cell autonomously, and more
specifically, does mtHtt-induced dysfunction of cortical
neurons lead to MSN dysfunction and degeneration, i.e.
‘murder’? There is evidence to support both mechanisms,
and it is highly likely that the two combine to create MSN
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dysfunction, and ultimately, death. For therapeutic reasons, it
remains critical to determine which gene alterations are cell
autonomous, and which are non-cell autonomous.
Transcriptional abnormalities appear to represent a core
pathological feature of HD (4,5) and genes showing enriched
expression in the striatum, including PPP1R1B, PENK, NGEF
and DRD2, appear to be especially affected by the mutant Htt
protein (6). Data obtained, however, have stopped short of dif-
ferentiating cell-autonomous versus cell non-autonomous
effects on gene transcription in vivo. Nonetheless, evidence
in favor of cell-autonomous effects include that lentiviral-
mediated delivery of mutant Htt to rat striatum results in a
progressive pathology characterized by the appearance of
ubiquitinated Htt aggregates, loss of dopamine- and
cAMP-regulated phosphoprotein of 32 kDa (DARPP-32)
staining and cell death (7,8) and cultured striatal cells in
which mutant Htt fragments are expressed show gene
expression deficits similar to those observed in human HD
subjects (9,10). Given that in vitro conditions may not accu-
rately represent the in vivo environment, especially in terms
of the normal development of striatal neurons and their affer-
ent and efferent projections, we sought to determine the extent
of cell-autonomous transcriptional dysregulation in vivo.
We previously generated an HD transgenic mouse ‘model’,
D9-N171-98Q (a.k.a. DE5), in which the forebrain expression
of the first 171 amino acids of human Htt with a 98Q repeat
expansion is limited to MSNs of the striatum (11). These
mice exhibit an HD-like phenotype, including failure to gain
weight after 10 months of age, motor impairment, the presence
of intranuclear inclusion bodies and disrupted expression of
several striatal-enriched genes. Here we have examined
genome-wide gene expression patterns in symptomatic DE5
transgenic mice to determine which transcripts are cell-
autonomously dysregulated in the striatum. We compared
these results with microarray data generated on the identical
array platform from R6/2 transgenic mice carrying two differ-
ent CAG repeat lengths (150 and 300), and with cultured
MSNs expressing mutant Htt and full-length HD models, to
further highlight pathways that may be dysregulated on a
non-cell-autonomous basis. Our findings demonstrate that
HD-induced dysregulation of the striatal transcriptome can
be fundamentally attributed to intrinsic effects of mutant Htt.
RESULTS
D9-N171-98Q transgenic mice
We have developed transgenic mice, D9-N171-98Q (sub-
sequently referred to as DE5), which, within the forebrain,
selectively express a pathogenic Htt species in the MSNs of
the striatum, specifically excluding the neocortex (11). We
have shown that these mice develop abnormal characteristics
of pan-cellular HD mouse models, including intranuclear
inclusion bodies, failure to gain weight after 10 months of
age and behavioral impairment, particularly on the rotarod
apparatus. Here we investigated the striatal genome-wide
expression profiles of these mice at 14 months of age using
microarray analysis. Overall, 1371 genes were found to be
altered in their expression in the striatum of DE5 mice com-
pared with wt controls [740 down-regulated; 631 up-regulated;
P-value , 0.05; abs (Log2 ratio) .0.10; Supplementary
Material, Table S1].
Perhaps as expected, a highly significant decrease in the
expression of genes showing striatal-enriched expression
(12) was detected in DE5 transgenic mice (n ¼ 26 genes; P
¼ 2.1E-15) (Table 1). These genes include prodynorphin
(Pdyn), protein phosphatase 1, regulatory (inhibitor) subunit
1B (Ppp1r1b: a.k.a. DARPP-32), A2a adenosine receptor
(Adora2a), the dopamine D2 receptor (Drd2) and proenkepha-
lin (Penk), all whose decreases in expression were validated
by qPCR in our previous publication (11). This is consistent
with findings from human subjects with HD (4,6) and other
HD transgenic mouse and cell culture models (13–16), includ-
ing other systems expressing a similar Htt fragment
(N171-82Q) (9,15). These findings indicate large-scale mol-
ecular dysfunction in the striatum of DE5 mice. Of note,
whereas changes in gene expression in pan-neuronal models
included decreases in many striatal-enriched, interneuron-
selective genes (Sst, Npy, Pvalb, Cck and Nos1), parallel
changes were absent from DE5 striata (with Pvalb mRNA
actually showing increased instead of decreased expression).
Direct comparisons with pan-neuronal HD mouse models
We compared striatal genome-wide expression profiles of
symptomatic DE5 mice with those from two different lines
of R6/2 transgenic mice, carrying either 150 CAG repeats,
‘Q150 mice’ (6 weeks of age), or 300 CAG repeats,
‘Q300 mice’ (5 months of age). These data were generated
on the same Illumina platform [Q300 from (17) and Q150,
this study] and analyzed in an identical manner in order to
allow for qualitative and quantitative comparisons with our
DE5 mouse data set. To visualize the correlation of fold-
change and to consider the specific direction of change
(increased versus decreased), these features are shown in
scatter plots (Fig. 1) and Venn diagrams (Fig. 2). We found
a highly significant overlap of differentially expressed probe
sets among the three mouse strains, with the greatest similarity
occurring between DE5 and R6/2-Q300 mice, with an overlap
of 415 probe set IDs (P, 4.29E-22) representing 30% of all
differentially expressed probe sets in DE5 transgenic mice.
Overall, high concordance is observed in the direction of the
expression change when comparing DE5 transgenic mice
with either R6/2 line; however, the magnitude of the
expression changes for both up- and down-regulated genes is
smaller in the DE5 transgenic mice compared with either
R6/2 strain. The top-ranked expression differences present in
all three mouse models are shown in Table 2, along with a
color-coded designation of direction and magnitude of
change. Perfect concordance was observed for all genes,
except Bin1, which was decreased in expression in DE5 trans-
genic and R6/2-Q150 transgenic mice, but elevated in
expression in R6/2-Q300 transgenic mice (Table 2).
We also compared expression profiles from DE5 transgenic
mice with those from older R6/2 mice [Q150 at 12 weeks of
age, using previously published data (13)]. Direct comparisons
should consider the caveat that this microarray data set was
performed on an Affymetrix platform and necessarily ana-
lyzed by an alternative method. Nevertheless, 50% of the
genes (n ¼ 821) found to be differentially expressed in DE5
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mice were also significantly altered in these later-stage R6/2
mice [Supplemental data sets 1 and 2 from (13)]. A list of
genes altered in DE5 but not in either R6 model is supplied
in Supplementary Material, Table S2.
Comparisons with in vitro striatal neurons overexpressing
mutant human Htt
Previous studies have examined transcriptome-wide changes
in rat primary striatal neurons expressing a similar N-terminal
fragment of the human mutant Htt protein (the first 171 amino
acids with an 82Q repeat expansion) (9). We compared gene
expression changes manifested in DE5 transgenic mice with
those exhibited in the Htt171-82Q-expressing striatal
neurons after correcting for species and microarray platform
differences and reanalyzing both microarray data sets by the
same method (see Materials and Methods). We identified
126 gene expression changes that were highly concordant
between in vivo and in vitro data (Supplementary Material,
Table S3). This list included several striatal-enriched genes,
such as Ppp1r1b, Baiap2, Adora2a and Ngef.
Correlations to human HD gene expression and full-length
HD mouse models
In order to determine to what extent the DE5 mice recapitulate
the gene expression profiles detected in human HD, we com-
pared gene transcriptome profiles from the striatum of DE5
transgenic mice with previously published microarray data
from human HD caudate samples (4). Human orthologs of
the top 200 differentially expressed mouse genes in the stria-
tum (including both increases and decreases) were mapped
and their expression differences screened in the published
human HD data set (4). A concordance coefficient was calcu-
lated taking into account concordant, as well as discordant,
changes as described previously (4). The concordance coeffi-
cient for our data set was 0.388 for down-regulated genes
and 0.201 for all genes, which is consistent with previous
studies reporting statistically significant concordant coeffi-
cients for other HD mouse models of 0.190–0.490 (4,18).
Hence, our findings indicate that DE5 transgenic mice demon-
strate a strong recapitulation of gene expression changes
observed in human patients with HD.
Microarray data from full-length HD models have also been
generated on the Affymetrix platform, where it was shown that
several full-length models at late stage share significant gene
expression changes with the R6/2 transgenic lines (13).
Accordingly, our DE5 mice also show overlapping gene
expression changes with these HD models; the greatest
overlap was observed with the 22-month CHL2Q150/Q150
mice where 248 (30%) down-regulated genes and 178 (24%)
up-regulated genes were shared between both models (Fig. 3
and Supplementary Material, Table S4).
Molecular features of cell autonomy
To probe the contributions of cell-autonomous mechanisms to
striatal pathology, we more closely examined those genes that
were significantly disrupted in the striatum of DE5 transgenic
mice and/or either of the R6/2 mouse lines. To this end, we
performed Gene Ontology (GO) screening of the genes signifi-
cantly altered in each mouse model, which revealed both
common and distinct functional categories associated with
DE5 and R6/2 transgenic mice. All three models showed
Table 1. Striatal-enriched genes showing altered expression in DE5 transgenic mice
Gene ID Gene description Accession# Log2 ratio P-value
Actn2 Alpha-actinin 2 NM_033268 20.229 0.00135
Adora2a Adenosine A2 receptor NM_009630 20.199 0.04774
Arpp21 Cyclic AMP-regulated phosphoprotein, 21 NM_033264 20.116 0.04151
Baiap2 BAI1-associated protein 2 NM_130862 20.301 0.00796
Bcl11b B-cell leukemia/lymphoma 11B NM_021399 20.259 0.04091
Calb1 Calbindin 1 NM_009788 20.116 0.04354
Dgke Diacylglycerol kinase NM_019505 20.268 0.00779
Drd2 Dopamine D2 receptor NM_010077 20.384 0.0402
Gng7 Gamma 7 subunit NM_010319 20.426 0.00596
Hpca Hippocalcin NM_010471 20.279 0.005
Klf16 Kruppel-like factor 16 NM_078477 20.493 0.00052
Ngef Neuronal guanine nucleotide exchange factor NM_019867 20.179 0.00187
Pde10a Phosphodiesterase 10A NM_011866 20.302 0.00562
Pde1b Phosphodiesterase 1b NM_008800 20.334 0.00013
Pdyn Prodynorphin NM_018863 20.408 0.00101
Penk Enkephalin NM_001002927 20.31 0.00479
Ppp1ca Protein phosphatase 1, catalytic subunit, alpha NM_031868 20.349 0.0033
Ppp1r1b DARPP-32 NM_144828 20.288 0.00929
Rarb RAR beta receptor 1 NM_011243 20.269 0.0411
Rasgrp2 RAS, guanyl releasing protein 2 NM_011242 20.123 0.00902
Rin1 Rab/Ras Inhibitor NM_145495 20.385 4.00E-05
Rgs9 Regulator of G-protein signaling 9 NM_011268 20.489 0.00069
Rxrg Retinoid X receptor gamma NM_009107 20.421 0.00254
Scn4b Sodium channel, type IV, beta BK001031 20.642 0.00081
Tesc Tescalcin NM_021344 20.544 0.00031
Zfp521 Zinc finger protein 521 NM_145492 0.247 3.00E-05
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significant association with signal transduction and calcium
signaling. However, only DE5 transgenic mice were associ-
ated with protein transport, axonogenesis and RNA splicing
(Fig. 4). Consistent with these findings, previous GO screening
of genes significantly altered in the Htt171-82Q-expressing
striatal neurons also revealed biological associations to neur-
onal signaling and divalent cation transport, as well as RNA
splicing/RNA processing and neurite development (9). Gene
expression changes in R6/2-Q150 mice were uniquely
related to categories of cell death and apoptosis (Fig. 4),
which might be connected to their rapid disease progression
and shorter lifespan compared with either R6/2-Q300 mice
or DE5 transgenic mice.
We next used Ingenuity Systems Pathways Analysis to
examine known canonical pathways that were significantly
correlated with genes differentially expressed in each line, as
well as those genes selectively altered in either DE5 or R6/2
lines. We focused specifically on those pathways that have
been implicated in cell-autonomous and non-cell-autonomous
pathophysiological mechanisms in HD. Some pathways were
associated with dysfunction in all three models, although in
several cases different genes within a given pathway were
found to be altered in their expression (Table 3). For
example, multiple genes in the calcium signaling pathway
were altered in all three transgenic lines, although eight
genes were uniquely altered in DE5 transgenic mice and five
in R6/2 transgenic mice. In other pathways, dysregulation
was more prominent in the pan-neuronal lines than in the
striatal-specific line. Most striking was dysregulation of
genes associated with dopamine and glutamate signaling,
which was greater in both R6/2 lines relative to the DE5
line. Notably, genes related to these pathways are also signifi-
cantly dysregulated in R6/2-150Q mice at later stages (13). On
the other hand, changes associated with oxidative phosphoryl-
ation and mitochondrial dysfunction were relatively more pro-
minent in DE5 transgenic mice, with several genes in this
pathway being altered in expression selectively in this
model. Genes in these pathways that were altered in the two
R6/2 lines differed from each other in addition to being dis-
tinct when compared with DE5 transgenic mice. Finally,
certain genes in the related peroxisome proliferator-activated
receptor (PPAR) pathway were altered in all lines, but
several were dysregulated only in DE5 transgenic mice,
including Nr2f1, Nfkbia, Pdgfa, Mras, Rxra, Map3k7ip1,
Ppargc1a and Ep300 (Table 3; Fig. 5).
Real-time PCR expression validation
We validated the expression differences for 11 genes related to
these canonical pathways, including two striatal-enriched
genes (Pde1b and Rgs9), in the striata of DE5 transgenic
mice. These include the ATP synthase, H+ transporting, mito-
chondrial F0 complex, subunit g (Atp5l), cytochrome c
oxidase, subunit VI a, polypeptide 1 (Cox6a1), cytochrome c
oxidase, subunit VIIa 1 (Cox7a1), cytochrome c oxidase,
subunit XVII assembly protein homolog (Cox17), NADH
dehydrogenase (ubiquinone) 1 alpha subcomplex, 2
(Ndufa2), NADH dehydrogenase (ubiquinone) 1, subcomplex
unknown, 1 (Ndufc1), NADH dehydrogenase (ubiquinone) 1,
subcomplex unknown, 2 (Ndufc2), nuclear receptor subfamily
2, group F, member 1 (Nr2f1), muscle and microspikes RAS
(Mras), mitogen-activated protein kinase kinase kinase 7 inter-
acting protein 1 (Map3k7ip1) and PPAR, gamma, coactivator
1 alpha (Ppargc1a). Eight of these genes showed validated
expression differences consistent with the microarray results:
Rgs9, Pde1b, Atp5l, Ndufc1, Mras, Nr2f1, Map3k7ip1 and
Ppargc1a (Fig. 6).
DISCUSSION
To elucidate the extent of cell-autonomous transcriptional
alterations in HD, we performed genome-wide expression pro-
filing of striatal tissue from DE5 transgenic mice. Importantly,
this is the first microarray study performed in an in vivo
‘striatal-specific’ genetic HD model. In this study, we demon-
strate a relatively high degree of overlap of changes in gene
expression in DE5 transgenic mice, a forebrain striatal-specific
mouse model of HD expressing the Htt N171 fragment and
two transgenic pan-cellular R6 models, human caudate and
Htt N171 fragment-expressing cultured striatal neurons (9).
Collectively, these data provide strong evidence that intrinsic
effects of mutant Htt are sufficient to result in transcriptional
alterations in several pathways relevant to HD pathology.
Conversely, these data suggest that expression of mutant Htt
Figure 1. Scatterplots showing concordant and discordant changes of the overlap of differentially expressed genes between DE5 transgenic and the R6/2 lines.
Log2 ratios for the gene expression changes for each comparison are shown, with each circle representing an individual gene. (A) Overlap between DE5 and R6/
2-Q150 transgenic mice (n ¼ 392 genes); (B) overlap between DE5 and R6/2-Q300 transgenic mice (n ¼ 511 genes).
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in the cortex is not required for most of the transcriptional dys-
regulation present in mouse models of HD.
Transcriptional effects of the cortex on the striatum in HD
may arise at least in part from decreased synthesis and trans-
port of brain-derived neurotrophic factor (BDNF) (18), and
it has been suggested that cortical-specific deletion of BDNF
mimics the pattern of transcriptional dysregulation in HD
(12). Importantly, DE5 transgenic mice express normal
levels of cortical BDNF and striatal trkB mRNA (11). More-
over, early embryonic deletion of BDNF may not accurately
represent the pattern of decreased BDNF noted in HD. Of
note, however, many of the striatal-enriched genes are also
regulated by BDNF (19), and a decrease in this trophic
factor may contribute to a greater magnitude of the alterations
in pan-neuronal HD models. It is also possible that the magni-
tude of these alterations would be greater in older DE5 mice
than those utilized in this study, since DE5 mice have a
normal lifespan.
Other mechanistic candidates leading to selective neuronal
vulnerability in HD include mitochondrial dysfunction that
induces energy deficits, increased oxidative stress and abnorm-
alities of calcium signaling. Pathways associated with both
cell- and non-cell-autonomous components include glutamate
and dopamine neurotransmission (20). We therefore compared
and contrasted changes in gene expression in these canonical
pathways among the different mouse models. We also
included the PPAR pathway, as it potentially unites transcrip-
tional dysregulation with mitochondrial dysfunction (21). We
anticipated that changes in gene expression associated with
mitochondrial dysfunction and oxidative stress, and the
responses to these stressors, would be largely cell autonomous,
resulting in a high degree of overlap between the DE5 and R6/
2 transgenic models. It was therefore surprising to discover
that levels of a number of genes in these pathways were
altered only in the DE5 transgenic line, including the
qPCR-validated Atp5l, Ndufac1 and Mras, despite a longer
polyglutamine repeat and greater symptomatology in the R6
transgenic models. This suggests that mitochondrial deficits
and oxidative stress are prominent features of intrinsic striatal
dysfunction. The fact that other genes associated with these
functions are altered in their expression in R6/2 suggests
that non-cell-autonomous effects might both exacerbate
and compensate for this dysfunction. Of note, however,
Mras, whose protein product may be required for
neurotrophic signaling and dendritic remodeling but is also
expressed in glia (22), is uniquely highly down-regulated in
the DE5 model.
In the calcium signaling pathway, the expression profiles of
the three mouse models are highly shared, implying a substan-
tial degree of cell-autonomous changes related to this
pathway. This is in contrast to the glutamate and dopamine
receptor signaling pathways for which the greatest number
of gene expression changes occurred in R6/2 transgenic
mice and very few occurred in DE5 transgenic mice. As
increased sensitivity to excitotoxity appears to result from
combinations of increased cortical glutamate neurotrans-
mission and mislocalization of MSN glutamate receptor sub-
types in the extra-synaptic region (reviewed in 23), which
may not be reflected by transcriptional dysregulation, these
results do not obviously allow for a prediction regarding sen-
sitivity to glutamate excitotoxicity in the DE5 mouse. Perhaps
not surprisingly, although Drd2, Rgs9 and Ppp1r1b mRNAs
are decreased in the striatum of DE5 transgenic mice, many
more genes in the dopamine receptor signaling pathway are
dysregulated in R6/2 compared with DE5 striatum, probably
reflecting trans-synaptic regulation and/or compensatory
responses to reduced dopaminergic input (24).
As noted above, we found a substantial overlap of gene
expression differences between DE5 transgenic mice and
Htt171-82Q-expressing primary striatal cultures. Furthermore,
we found that DE5 transgenic mice showed a similar enrich-
ment of GO categories to those reported previously from
these in vitro studies. In particular, gene expression changes
unique to DE5 transgenic mice and cultured striatal neurons,
but not R6/2 mice, were associated with protein transport,
axon development and RNA splicing (9). There are actually
fewer changes in the DE5 model relative to the cultured
neurons. We hypothesize that this is due to the somewhat
immature nature of the neurons in vitro, and also to the fact
that by definition, they are removed from their normal devel-
opmental and adult environment and changes are, therefore,
both cell autonomous and independent of brain circuitry.
Another previous microarray study reported transcription
changes from rat clonal striata-derived cells expressing an N-
terminal 548-amino acid Htt fragment under the control of a
doxycycline-regulated promoter (10). These studies revealed
altered expression of genes involved in cell signaling, tran-
scription, lipid metabolism as well as RNA processing, con-
sistent with our findings. Overall, of the 80 gene
expression abnormalities reported, we found 6 genes, includ-
ing 2 lipid-related genes, Acat2 and Fasn, that were also dys-
regulated in the DE5 transgenic mice.
Of the altered genes that are ubiquitously expressed, there
were important differences in the direction of change in a
subset of transcripts that may reflect compensatory changes.
For example, Ppargc1a is a member of the PPAR-regulated
pathway, and its down-regulation in MSNs is hypothesized
to play a causative role in HD pathophysiology (25–28). In
DE5 transgenic mice, however, Ppargc1a mRNA is
up-regulated, whereas it is unchanged in the R6 transgenic
models in this study. Interestingly, Nr2f1 expression is also
up-regulated in DE5 mice and Map3k7ip1 is down-regulated,
but both are unchanged in the R6 models, which could serve to
balance the impairment of Ppargc1a-associated activity in
Figure 2. Venn diagrams depicting overlap between DE5, R6/2-Q150 and R6/
2-Q300 for both down-regulated and up-regulated genes.
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DE5 mice and subsequent down-regulation of protective mito-
chondrial activity. Another example of an abnormality in the
oxidative phosphorylation pathway in DE5 mice only is
Ndufc1, which follows the same pattern as Ppargc1a
(Fig. 6), The functional implications, therefore, may actually
be similar to those models in which Ppargc1a is down-
regulated and may indicate altered mitochondrial energy
metabolism in DE5 transgenic mice.
Mutant Htt protein interacts with multiple transcription
factors, most of which are not cell specific, e.g. the cAMP
response element-binding protein (CREB)-binding protein,
Specificity protein 1 (Sp1), TATA binding box protein,
Bcl11b, repressor element-1 transcription factor/neuron
restrictive silencer factor and widely expressed
components of the basal polymerase II transcriptional machin-
ery (29–31). Overall, the genome-wide transcriptome
Table 2. Top expression changes significantly altered in all three HD mouse lines
The top-ranked gene expression changes present in all three mouse models are shown according to UniGene ID symbol, along with a color-coded designation of
direction and magnitude of change.
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changes induced by mutant Htt in DE5 cannot yet be ascribed
to a particular transcription factor regulatory network (32–35).
A final distinction worthy of consideration is the cellular
localization of expression of genes of interest. The D9 promo-
ter driving Htt expression in DE5 transgenic mice does not
direct expression to striatal interneurons or to glia (36). Striatal
GABAergic/parvalbumin interneurons receive direct, conver-
gent cortical input (37) and are in fact highly sensitive in
HD and in models of excitotoxicity (38). In mouse HD
models, Pvalb gene expression is usually decreased;
however, in the DE5 model, Pvalb expression is increased.
As noted above, PGC1a mRNA is also increased, which
may be driving the Pvalb gene (39). These data imply that
in the DE5 mouse, transcriptome alterations in these inter-
neurons are mediated by cell–cell interactions, whereas
there may be more direct, cell-autonomous alterations when
mutant Htt is expressed in a pan-cellular distribution. In
regards to glia, it has recently been demonstrated that selective
expression of mutant Htt in glia results in a distinct phenotype
and further exacerbates symptoms in the N171-82Q transgenic
mouse (40,41). Importantly, the Nrf2-mediated protective
pathway is largely localized to astrocytes (42), so it will be
important to determine in which cell types(s) alterations in
expression of genes in this pathway are occurring in all HD
mouse models.
In summary, our data are consistent with the notion that
transcriptional dysregulation in HD MSNs in vivo is largely
cell autonomous in specific canonical pathways, and largely
non-cell autonomous in others. They are also consistent with
our previous findings regarding the nature and severity of
the motor deficit in the DE5 transgenic mouse, particularly
when directly compared with the prp-N171-82Q model (11).
Our underlying assumption is that the changes noted in the
DE5 mouse striatum are cell autonomous, but can simul-
taneously be compensating for cell-intrinsic abnormalities.
The converse is also true, i.e. compensatory pathways may
also normalize some of the anticipated alterations. Conversely,
in pan-neuronal models, e.g. R6/2, transcriptome alterations
that may occur on a cell-autonomous basis may be ‘masked’
by opposing, non-cell-autonomous effects of the mutation on
the MSN, resulting in gene alterations that are unique to
DE5 transgenic mice. These latter alterations may also be
compensatory, and may be either beneficial or deleterious.
Finally, it is possible that the response of individual changes
may differ based on the Htt fragment length, although pub-
lished data do not support a major role for the fragment
length. Overall, this situation is perhaps most similar to what
has been hypothesized for the etiology of amyotrophic
lateral sclerosis (43), in which the pathophysiological pro-
cesses are initiated in highly vulnerable neuronal subtypes,
but progression proceeds more rapidly via non-cell-
autonomous mechanisms. Therapeutic targeting of cell- or
non-cell-autonomous sites will, therefore, depend on which
pathway(s) is the desired target.
MATERIALS AND METHODS
DE5 transgenic mice
Creation and characterization of the D9-N171-98Q (a.k.a.
DE5) mouse line has been previously reported (11). Male
DE5 transgenic mice and non-transgenic controls (i.e. wt) (n
¼ 3 to 4 per genotype) were used for the microarray analysis.
Mice were sacrificed at 14 months of age, a time at which
HD-like phenotypes are clearly manifested (11).
Microarray analysis: comparisons with the R6/2 line
Total RNA was extracted from the striatum of wt and DE5 trans-
genic mice using the Nucleospin RNA kit (BD Biosciences, San
Jose, CA, USA). RNA quantity was assessed with Nanodrop
(Nanodrop Technologies) and quality with the Agilent Bioana-
lyzer (Agilent Technologies). Total RNA (200 ng) was ampli-
fied, biotinylated and hybridized on Illumina Mouse-8 V2
Beadchips, querying the expression of 22 000 Refseq tran-
scripts according to the manufacturer’s protocol. Slides were
scanned using Illumina BeadStation and signal extracted
using Illumina BeadStudio software (Illumina, San Diego,
CA, USA). Raw data were analyzed using Bioconductor
packages (44). Quality assessment was performed looking at
the inter-array Pearson correlation and clustering based on top
variant genes was used to assess overall data coherence. Con-
trast analysis of differential expression was performed using
the ‘limma’ package (45). After linear model fitting, a Bayesian
estimate of differential expression was calculated. Data analysis
Figure 3. Venn diagrams depicting overlap between DE5, Hdh (Q92/Q92) and
CHL2 (Q150/Q150) for both down-regulated and up-regulated genes.
Figure 4. GO categories significantly associated with genes dysregulated in
DE5 and R6/2 transgenic mice. Specific categories are listed along the
x-axis, with the number of genes per category along the y-axis.
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was aimed at (i) identifying transcriptional changes in the DE5
transgenic compared with wt mice, and (ii) comparing striatal
gene expression profiles of DE5 transgenic mice with those pro-
files previously generated from the striata of two different lines
of R6/2 mice generated on the same platform (17 and Luthi-
Carter, Kuhn, unpublished data). Several criteria were con-
sidered for identifying differentially expressed genes, including
P-value cut-offs ranging fromP, 0.001 to,0.05 and different
log2 ratio cut-offs.
Microarray analysis: comparisons with in vitro cells
Gene expression profiles (n ¼ 7) obtained from DE5 and wt
mice were normalized using robust multi-array average and
Table 3. Canonical pathways associated with shared and unique expression profiles of HD mice
Pathway DE5 HD mouse expression profile R6/2 only (both
Q150 and Q300,
not DE5)
R6/2-Q150 R6/2-Q300 DE5 only
Dopamine receptor
signaling
PPP2R5C, PPP1R1B,
PPP2R5D, PPM1L,
PPP1CA, DRD2
PPP1R14C, PPP1R1B,
PPP2R2A, PPP2R5D,
PPP1R3C, PPP1CB,
SLC18A3, DRD1A, DRD2,
PPP2R5A,TH, PPP2R4,
ADCY5, PRKAR1B,
PPP1R12A, PPP1CA, SPR
ADCY9, GCH1, PPP1R1B,
PPP2CA, PPP2R2A,
PPP2R5D, PPP1R3C,
PPP1CB, SLC18A3,
PPP1R14A, DRD1A,
DRD2, COMT, SPR, DRD4,
PPP2R5E, PPP1CA
PPPM1L PPP2R2A,
PPP1R3C,
SLC18A3,
SPR DRD1A,
PPP1CB
Glutamate receptor
signaling
SLC17A6, GRM8,
HOMER1, GNG7
GRIA1, GRIA3, GRID1,
GRM5, GNG7, HOMER1,
SLC1A3
CAMK4, GRM1, GRIA1,
CALM2, SLC1A1, GRIP1,
GRM4, GNG7, GNB1,
GRIK5, GRIN2C, GLUL,
SLC1A2, HOMER1
SLC17A6, GRM8 GRIA1
Calcium signaling RAP1B, TNNT1, CHRNA4,
RCAN2, ACTA2, TPM2,
TRPC4, ITPR1, MYL6B,
ATP2A2, EP300,
CHRNB2, HDAC11,
RYR1, MEF2C, ACTA1
TNNT1, CAMK1, MYL6,
MAPK1, RCAN2, TNNT2,
TPM2, MYH7, ITPR1,
ATP2A2, CAMK2A,
CAMKK1, GRIA1,
PRKAR1B, RYR1, MYL4,
ASPH, PPP3CA,
CAMKK2, CAMK2B,
GRIA1
TNNT1, CAMK4, GRIA1,
CREBBP, HDAC1, CREB3,
TNNT2, MAPK6, SLC8A3,
CALM2, TPM2, MAPK12,
ATP2A2, ATP2B2, TRPC7,
CAMK2A, GRIN2C,
HDAC11, CAMKK1, RYR3,
RCAN3, RYR1, PPP3CA,
CAMKK2
RAP1B, CHRNA4,
CHRNB2,
ACTA1, ACTA2,
TRPC4, MEF2C,
EP300
CAMK2A,
CAMKK1,
TNNT2,
PPP3CA,
CAMKK2
Mitochondrial
dysfunction
MAP2K4, COX17,
COX6A1, PRDX5,
GPD2, MAPK10,
UQCRB, OGDH, SNCA,
COX7A1, TXNRD2,
NDUFA2
UQCRH, NDUFB3, UCP2,
CASP9, NDUFA11,
PRDX5, NDUFA6,
NDUFA3, GPX4,
NDUFS3, PSEN1
NDUFAF1, UQCRH,
NDUFA5, CASP3,
NDUFS7, MAPK9, BACE2,
OGDH, MAPK12,
COX7A1, NDUFS3
MAP2K4, COX6A1,
MAPK10, SNCA,
TXNRD2,
NDUFA2, GPD2,
UQCRB
UQCRH,
NDUFS3
Oxidative
phosphorylation
NDUFC1, ATP6V1C2,
COX17, COX6A1,
NDUFC2, TCIRG1,
ATP5L, UQCRB,
COX7A1, NDUFA2
UQCRH, NDUFB3,
NDUFA11, ATP5G1,
NDUFA6, ATP5H,
ATP6V0D1, NDUFA3,
ATP5G2, ATP6V1G2,
ATP6AP1, NDUFS3
ATP5G1, ATP6AP1, ATP6V1,
NDUFS3, UQCRH,
COX7A1, COX17
NDUFC1,
ATP6V1C2,
COX6A1,
NDUFC2,
TCIRG1, ATP5L,
NDUFA2
UQCRH,
ATP5G1,
ATP6AP1,
NDUFS3
NRF2-mediated
oxidative stress
response
MAP2K4, GSTA3, GSTA4,
GSTM1, USP14,
ACTA2, DNAJC6,
HERPUD1, GSTO1,
EP300, CUL3, GSTA4,
MRAS, ACTA1, EPHX1
GSTA3, USP14, MAPK1,
DNAJB4, RRAS, PIK3C2G,
HSPB8, HRAS, HERPUD1,
JUN, MGST2, MAP2K2,
KEAP1, STIP1, DNAJC8,
VCP, PRKCH, DNAJB5,
CBR1, MGST3, EPHX1,
PRKCB, DNAJC4
GSTA3, GSTM1, GSTM5,
RRAS, CREBBP, MAPK6,
HRAS, MAPK9, MAPK12,
GSTO1, PIK3R3, RRAS2,
DNAJC8, PIK3R2, AOX1,
GSK3B, EPHX1, PRKCA,
PRKCB, DNAJC4,
KEAP1,VCP
MAP2K4, GSTA4,
ACTA2, MRAS,
ACTA1, EP300
DNAJC4, RRAS,
DNAJC8,
KEAP1, VCP,
HRAS,
PIK3R2,
PRKCB
Neurotrophin/TRK
signaling
MAP2K4, CDC42, NTRK3,
MRAS
JUN, MAP2K2, MAPK1,
GAB1, RRAS, PIK3C2G,
HRAS, PIK3R2
PIK3R3, RRAS2, CDC42,
RRAS, NTRK3, CREB3,
MAPK6, HRAS, PIK3R2,
MAPK12
MAP2K4, MRAS RRAS, HRAS,
PIK3R2
PPAR signaling NR2F1, NFKBIA, PDGFA,
MRAS, NCOR1, RXRA,
MAP3K7IP1,
PPARGC1A, EP300
JUN, MAP2K2, MAPK1,
RRAS, HRAS, NCOR,
MAP3K14
MAP3K14, RRAS2, RRAS,
CREBBP, MAPK6, NR1H3,
HRAS, MAPK12,
TNFRSF11B
NR2F1, NFKBIA,
PDGFA, MRAS,
RXRA,
MAP3K7IP1,
PPARGC1A,
EP300
MAP3K14,
RRAS, HRAS
Canonical pathways analysis was run using Ingenuity Systems Pathway Analysis. Those pathways significantly associated with transcriptome profiles of the
indicated condition are shown. Genes are indicated by their Official UniGene symbol. NS, not significant. Red indicates those genes upregulated in expression,
while green indicates down-regulated genes.
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log2-transformed using the Bioconductor package ‘beadarray’
(46). We performed differential expression analysis between
DE5 (n ¼ 4) and wt (n ¼ 3) mice using the Bioconductor
package ‘limma’ (45) and adjusted P-values for multiple
testing (47). To assess the resemblance of gene expression
changes detected in DE5 mice and in a rat primary cell
culture model (N171-82Q versus N171-18Q, data from ref.
9), we mapped all Illumina probes onto orthologous Affyme-
trix probe sets on the Rat RAE230A array format using the
Bioconductor package ‘annotationTools’ (48). We then
mapped Illumina’s RefSeq transcript ID annotation
(Mouse-8 V2) to corresponding mouse gene IDs using gen-
e2accession obtained from Entrez gene (on 6 August 2010).
Orthologous rat genes were obtained using HomoloGene
(build 64) and mapped to Affymetrix probe sets present on
the rat microrray using Affymetrix annotation (build 30).
Starting from 22 744 Illumina probes annotated with a
RefSeq ID, we obtained 21 716 corresponding gene IDs that
could be mapped onto 18 352 rat orthologous gene IDs. A
total of 14 572 of these had at least one probe set on the Affy-
metrix microarray. Note that using the RefSeq IDs provided in
Illumina’s annotation (instead of gene IDs) allowed us to
perform a more complete mapping since 5580 probes that
were annotated with a RefSeq transcript were not annotated
with a gene ID. This Illumina probe to Affymetrix probe set
mapping was then used to align differentially expressed
genes in DE5 mice with orthologous Affymetrix probe sets
on the Rat RAE230A array.
Pathway analyses
GO terms were identified using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) (http://da
vid.abcc.ncifcrf.gov/) to understand the potential biological
relevance of differentially expressed genes. Canonical
pathway analysis was performed using Ingenuity Systems
Pathway Analysis.
Microarray data concordance
We assessed the correlation between gene expression changes
detected in DE5 transgenic mice compared with those
observed in human post-mortem caudate by calculating the
concordance coefficient, as described previously (13). The
concordant regulation was defined as a pair of orthologous
probe sets reporting same-direction differential expression
between disease and control (i.e. both up-regulated or both
down-regulated) where the human probe set showed a signifi-
cant expression change (FDR P-value , 0.05) (14). Similarly,
discordant regulation was defined as two probe sets reporting
opposite sign regulations where the human probe set showed a
significant expression change (FDR P-value , 0.05). The con-
cordance coefficient, c, was defined as:
c = # concordant− # discordant
N
Figure 5. The PPAR pathway. Schematic depiction of the PPAR pathway with those genes highlighted that are selectively altered in their expression in DE5
transgenic mice. Red indicates an up-regulation of gene expression; green, a down-regulation. PPARa (Ppargc1a), peroxisome proliferator-activated receptor
gamma coactivator 1-alpha; Coup-tf (Nr2f1), nuclear receptor subfamily 2, group F, member 1; Rxra (Rxra), retinoid X receptor alpha; Ncor1 (Ncor1), nuclear
receptor co-repressor 1; Mras (Mras), muscle and microspikes RAS; Pdgfa (Pdgfa), platelet derived growth factor, alpha; TAB1 (Map3k7ip1),
TGF-beta-activated kinase 1/MAP3K7 binding protein 1; Nfkbia (Nfkbia), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor,
alpha. Pathway depiction reproduced with permission from Ingenuity Systems Analysis (# 2000–2011 Ingenuity Systems, Inc. All rights reserved).
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The #concordant is the number of concordant orthologous
probe set pairs, the #discordant the number of discordant
orthologous probe set pairs and N the number of mouse
probe sets selected for the comparison. Of the top 200 signifi-
cantly altered genes in the DE5 transgenic mice, 16 gene IDs
had no human homolog or were not on the Illumina arrays,
leaving 184 genes for the comparison against human.
Real-time PCR experiments
Real-time PCR experiments were performed using the ABI
PRISMs 7900HT Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) as described previously
(12). Amplification was performed on a cDNA amount equiv-
alent to 25 ng of total RNA with 1 x SYBRw Green universal
PCR Master mix (Applied Biosystems) containing deoxyribo-
nucleotide triphosphates, MgCl2, AmpliTaq Gold DNA poly-
merase and forward and reverse primers. Specific primers
for each mouse gene endogenous control were designed
using Primer Express 1.5 software and their specificity for
binding to the desired sequences was searched against the
NCBI database (Supplementary Material, Table S5). Standard
curves were generated for each gene of interest using serial
dilutions of mouse cDNAs. Experimental samples and
no-template controls were run in duplicate. The PCR cycling
parameters were: 508C for 2 min, 958C for 10 min, and 40
cycles of 948C for 15 s, 608C for 1 min. The amount of
cDNA in each sample was calculated using SDS2.1 software
by the comparative threshold cycle (Ct) method and expressed
as 2exp(Ct) using hypoxanthine guanine phosphoribosyl trans-
ferase (Hprt) as an internal control. Student’s t-test (uni-
directional) was used to determine significant differences in
expression between non-transgenic and DE5 transgenic
mice. Statistical analyses were performed using GraphPad
software (GraphPad Prism, San Diego, CA, USA).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
Figure 6. Expression alterations of genes associated with various canonical pathways in DE5 transgenic mice. Real-time PCR analysis was performed for the
indicated genes (indicated by their official UniGene ID) on RNA samples from striatum of DE5 transgenic mice. Data are depicted as fold-change of the mean
expression level+SEM (n ¼ 4 mice per group). The relative abundance of each gene expression was normalized using Hprt. Asterisks denote significant differ-
ences from wt or control subjects as determined by unidirectional Student’s t-tests: ∗P, 0.05; ∗∗P, 0.005; +P, 0.06.
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